FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jeffrey Lancet

Research Profile

Chemicals & Drugs

Disorders

Procedures

Concepts & Ideas

Co-author Network

Publications

TOP 3
Vu Duong; Pearlie K Epling-Burnette; Teresa Field; Jeffrey E Lancet; Alan F List; Janelle Perkins; Ling Zhang; Najla H Al-Ali; Ezzideen Alrawi; Rami S Komrokji
Outcome of azacitidine treatment in patients with therapy-related myeloid neoplasms with assessment of prognostic risk stratification models.
Kristin M Phillips; Javier Pinilla-Ibarz; Brent Small; Lubomir Sokol; Eduardo Sotomayor; Kendra Sweet; Sara Tinsley; Heather Jim; Rami S Komrokji; Jeffrey E Lancet; Morgan R Lee; Paul B Jacobsen
Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison.
Vu Duong; Michael V Jaglal; Vishakha Kale; Rami S Komrokji; Jeffrey E Lancet; Ling Zhang; Alan F List
Phase II pilot study of oral dasatinib in patients with higher-risk myelodysplastic syndrome (MDS) who failed conventional therapy.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jeffrey Lancet (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Vu Duong; Pearlie K Epling-Burnette; Teresa Field; Jeffrey E Lancet; Alan F List; Janelle Perkins; Ling Zhang; Najla H Al-Ali; Ezzideen Alrawi; Rami S Komrokji
Outcome of azacitidine treatment in patients with therapy-related myeloid neoplasms with assessment of prognostic risk stratification models.
Leukemia research 2013;37(5):510-5.
2013: Kristin M Phillips; Javier Pinilla-Ibarz; Brent Small; Lubomir Sokol; Eduardo Sotomayor; Kendra Sweet; Sara Tinsley; Heather Jim; Rami S Komrokji; Jeffrey E Lancet; Morgan R Lee; Paul B Jacobsen
Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2013;21(4):1097-103.
2013: Vu Duong; Michael V Jaglal; Vishakha Kale; Rami S Komrokji; Jeffrey E Lancet; Ling Zhang; Alan F List
Phase II pilot study of oral dasatinib in patients with higher-risk myelodysplastic syndrome (MDS) who failed conventional therapy.
Leukemia research 2013;37(3):300-4.
2013: S Wei; L Zhang; J Zhou; J P Maciejewski; K McGraw; D Sallman; M Sekeres; L Sokol; H Wang; D Billingsley; G Caceres; X Chen; J Clark; Julie Y Djeu; Erika Eksioglu; Pearlie K Epling-Burnette; N Fortenbery; Rami S Komrokji; Jeffrey E Lancet; A List
Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion.
Oncogene 2013;32(9):1110-20.
2012: Mikkael A Sekeres; Ali Tabarroki; Ramon Tiu; Valeria Visconte; Hideki Makishima; Jennifer Paleveda; Ronald Paquette; Anjali S Advani; Manuel Afable; David Cuthbertson; Ricki Englehaupt; Andres Jerez; Joyce Juersivich; Rami S Komrokji; Jeffrey E Lancet; Alan F List; Jaroslaw P Maciejewski
Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.
Blood 2012;120(25):4945-51.
2012: Rami S Komrokji; Jeffrey E Lancet; Najla H Al Ali; Maria Corrales-Yepez; Pearlie K Epling-Burnette; Mohamed A Kharfan-Dabaja; Eric Padron; Javier Pinilla-Ibarz; Dana E Rollison; Ling Zhang; Alan F List
Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes.
American journal of hematology 2012;87(11):1006-9.
2012: Rami S Komrokji; Jeffrey E Lancet; Nianhang Chen; Richard Lush; Jennifer Paleveda; Hussain I Saba; Arlene S Swern; Alan F List
Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome.
Blood 2012;120(17):3419-24.
2012: Rami S Komrokji; Jeffrey E Lancet; Maria Corrales-Yepez; Teresa Fields; Mohammad Kharfan-Dabaja; Eric Padron; Najla Al Ali; Alan F List
Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome.
Cancer 2012;118(10):2659-64.
2011: Taiga Nishihori; Jose L Ochoa-Bayona; Domenico Coppola; Hugo F Fernandez; Rami S Komrokji; Jeffrey E Lancet; Mohamed A Kharfan-Dabaja
Hepatobiliary manifestations of acute myeloid leukemia.
Leukemia research 2011;35(6):e81-3.
2011: Celeste Bello; Daohai Yu; Rami S Komrokji; Weiwei Zhu; Gene A Wetzstein; Alan F List; Jeffrey E Lancet
Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome.
Cancer 2011;117(7):1463-9.
2011: Samantha L Price; Jeffrey E Lancet; Timothy J George; Gene A Wetzstein; Alan F List; Viet Q Ho; Hugo F Fernandez; Javier Pinilla-Ibarz; Mohamed A Kharfan-Dabaja; Rami S Komrokji
Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens.
Leukemia research 2011;35(3):301-4.
2011: Mohamed A Kharfan-Dabaja; Julio C Chavez; Daohai Yu; Weiwei Zhu; Eduardo I Fernandez-Vertiz; Janelle Perkins; Jamie Shapiro; Ryan Bookout; Lia Perez; Hugo F Fernandez; Rami S Komrokji; Jeffrey E Lancet; Linda Brand; Teresa Field; Ernesto Ayala; William Janssen; Alan F List; Claudio Anasetti
Severe hypoalbuminemia at day 90 predicts worse nonrelapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2011;17(3):384-93.
2010: T Field; J Perkins; Y Huang; Mohamed A Kharfan-Dabaja; M Alsina; E Ayala; H F Fernandez; W Janssen; Jeffrey E Lancet; L Perez; D Sullivan; A List; Claudio Anasetti
5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation.
Bone marrow transplantation 2010;45(2):255-60.
2010: Rami S Komrokji; Jeffrey E Lancet; Alan F List
Lenalidomide in myelodysplastic syndromes: an erythropoiesis-stimulating agent or more?
Current hematologic malignancy reports 2010;5(1):9-14.
2009: Jeffrey E Lancet; Judith E Karp
Novel postremission strategies in adults with acute myeloid leukemia.
Current opinion in hematology 2009;16(2):105-11.
2008: Judith E Karp; Jeffrey E Lancet
Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia.
Biologics : targets & therapy 2008;2(3):491-500.
2008: mitch raponi; Jeffrey E Lancet; Hongtao Fan; Lesley Dossey; Grace Lee; Ivana Gojo; Eric J Feldman; Jason Gotlib; Lawrence E Morris; Peter L Greenberg; John J Wright; Jean-Luc Harousseau; Bob Löwenberg; Richard M Stone; Peter De Porre; Yixin Wang; Judith E Karp
A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia.
Blood 2008;111(5):2589-96.
2007: Judith E Karp; Jeffrey E Lancet
Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies.
Cancer investigation 2007;25(6):484-94.
2007: Jean-Luc Harousseau; Jeffrey E Lancet; Josy Reiffers; Bob Lowenberg; Xavier Thomas; Francoise Huguet; Pierre Fenaux; Steven Zhang; Wayne Rackoff; Peter De Porre; Richard Stone
A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia.
Blood 2007;109(12):5151-6.
2007: mitch raponi; Jean-Luc Harousseau; Jeffrey E Lancet; Bob Löwenberg; Richard Stone; Yi Zhang; Wayne Rackoff; Yixin Wang; David Atkins
Identification of molecular predictors of response in a study of tipifarnib treatment in relapsed and refractory acute myelogenous leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(7):2254-60.
2007: Jeffrey E Lancet; Ivana Gojo; Jason Gotlib; Eric J Feldman; Jacqueline Greer; Jane L Liesveld; Laura M Bruzek; Lawrence Morris; Youn Park; Alex A. Adjei; Scott H Kaufmann; Elizabeth Garrett-Mayer; Peter L Greenberg; John J Wright; Judith E Karp
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia.
Blood 2007;109(4):1387-94.
2005: Judith E Karp; Jeffrey E Lancet
Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies.
Future oncology (London, England) 2005;1(6):719-31.
2005: Jane L Liesveld; Karen Rosell; Chaohui Lu; Jeremy Bechelli; Gordon Phillips; Jeffrey E Lancet; Camille N Abboud
Acute myelogenous leukemia--microenvironment interactions: role of endothelial cells and proteasome inhibition.
Hematology (Amsterdam, Netherlands) 2005;10(6):483-94.
2005: Judith E Karp; Jeffrey E Lancet
Targeting the process of farynesylation for therapy of hematologic malignancies.
Current molecular medicine 2005;5(7):643-52.
2005: Jeffrey E Lancet; Judith E Karp
Farnesyl transferase inhibitors in myeloid disorders.
Oncology (Williston Park, N.Y.) 2005;19(8):1043-9; discussion 1049-50, 1053-4.
2004: Gordon L Phillips; Camille N Abboud; Steven H Bernstein; J W Friedberg; Jainulabdeen J Ifthikharuddin; Jeffrey E Lancet; Jane L Liesveld; E Spreng; V Johnson; M Chapman; David H Vesole
Phase I study for poor-prognosis lymphoma: augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation--a preliminary report.
Seminars in oncology 2004;31(6 Suppl 18):59-61.
2004: mitch raponi; Robert T Belly; Judith E Karp; Jeffrey E Lancet; David Atkins; Yixin Wang
Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia.
BMC cancer 2004;4():56.
2004: Anne-Marie O'Farrell; Helene A Yuen; Beverly D Smolich; Alison L Hannah; Sharianne G Louie; Weiru Hong; Alison T Stopeck; Lewis R Silverman; Jeffrey E Lancet; Judith E Karp; Maher Albitar; Julie M Cherrington; Francis Giles
Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.
Leukemia research 2004;28(7):679-89.
2004: Judith E Karp; Jeffrey E Lancet
Farnesyltransferase inhibitors (FTIs) in myeloid malignancies.
Annals of hematology 2004;83 Suppl 1():S87-8.
2004: Maurizio Zangari; Elias Anaissie; Alison T Stopeck; Alyssa Morimoto; Nguyen Tan; Jeffrey E Lancet; Maureen Cooper; Alison L Hannah; Guillermo Garcia-Manero; Stefan Faderl; Andrew Lamb; Julie M Cherrington; Maher Albitar; Francis Giles
Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(1 Pt 1):88-95.
2003: Jeffrey E Lancet; Judith E Karp
Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy.
Blood 2003;102(12):3880-9.
2003: Ramalingam Rathnasabapathy; Jeffrey E Lancet
Management of acute myelogenous leukemia in the elderly.
Cancer control : journal of the Moffitt Cancer Center 2003;10(6):469-77.
2003: Jane L Liesveld; Jeffrey E Lancet; Karen Rosell; A Menon; Chaohui Lu; C McNair; Camille N Abboud; Joseph D Rosenblatt
Effects of the farnesyl transferase inhibitor R115777 on normal and leukemic hematopoiesis.
Leukemia 2003;17(9):1806-12.
2003: Jeffrey E Lancet; Judith E Karp
Farnesyl transferase inhibitors in myeloid malignancies.
Blood reviews 2003;17(3):123-9.
2003: Francis Giles; Alison T Stopeck; Lewis R Silverman; Jeffrey E Lancet; Maureen A Cooper; Alison L Hannah; Julie M Cherrington; Anne-Marie O'Farrell; Helene A Yuen; Sharianne G Louie; Weiru Hong; Jorge E Cortes; Srdan Verstovsek; Maher Albitar; Susan M O'Brien; Hagop M Kantarjian; Judith E Karp
SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.
Blood 2003;102(3):795-801.
2003: Rami S Komrokji; Jeffrey E Lancet; Raymond E Felgar; Nancy Wang; John M Bennett
Burkitt's leukemia with precursor B-cell immunophenotype and atypical morphology (atypical Burkitt's leukemia/lymphoma): case report and review of literature.
Leukemia research 2003;27(6):561-6.
2003: Francis Giles; Maureen A Cooper; Lewis Silverman; Judith E Karp; Jeffrey E Lancet; Maurizio Zangari; Paul J Shami; Khuda Dad Khan; Alison L Hannah; Julie M Cherrington; Deborah A Thomas; Guillermo Garcia-Manero; Maher Albitar; Hagop M Kantarjian; Alison T Stopeck
Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases.
Cancer 2003;97(8):1920-8.
2002: Jeffrey E Lancet; Joseph D Rosenblatt; Judith E Karp
Farnesyltransferase inhibitors and myeloid malignancies: phase I evidence of Zarnestra activity in high-risk leukemias.
Seminars in hematology 2002;39(3 Suppl 2):31-5.
2002: Jane L Liesveld; Camille N Abboud; Jainulabdeen J Ifthikharuddin; Jeffrey E Lancet; Lucy A Wedow; Jamie Oliva; Carol G Stamm; Diane Nichols
Oral valacyclovir versus intravenous acyclovir in preventing herpes simplex virus infections in autologous stem cell transplant recipients.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2002;8(12):662-5.
2001: Judith E Karp; Scott H Kaufmann; Alex A. Adjei; Jeffrey E Lancet; John J Wright; David W End
Current status of clinical trials of farnesyltransferase inhibitors.
Current opinion in oncology 2001;13(6):470-6.
2001: Judith E Karp; Jeffrey E Lancet; Scott H Kaufmann; David W End; John J Wright; K Bol; I Horak; Michael L Tidwell; Jane L Liesveld; Timothy J Kottke; D Ange; Laxmi N Buddharaju; Ivana Gojo; W Edward Highsmith; Robert T Belly; R J Hohl; M E Rybak; A Thibault; Joseph D Rosenblatt
Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.
Blood 2001;97(11):3361-9.
1998: Jeffrey E Lancet; Aaron P Rapoport; Ralph A. Brasacchio; Shirley Eberly; Richard F Raubertas; T Linder; Ann G Muhs; RE Duerst; Camille N Abboud; CH Packman; John F DiPersio; Louis S Constine; JM Rowe; Jane L Liesveld
Autotransplantation for relapsed or refractory Hodgkin's disease: long-term follow-up and analysis of prognostic factors.
Bone marrow transplantation 1998;22(3):265-71.